Withania somnifera (L.) Dunal (Indian ginseng, winter cherry, Solanaceae) is widely used in traditional medicine. Roots are either chewed or used to prepare beverages (aqueous decocts). The major secondary metabolites of Withania somnifera are the withanolides, which are C-28-steroidal lactone triterpenoids. Withania somnifera extracts exert chemopreventive and anticancer activities in vitro and in vivo. The aims of the present in silico study were, firstly, to investigate whether tumor cells develop cross-resistance between standard anticancer drugs and withanolides and, secondly, to elucidate the molecular determinants of sensitivity and resistance of tumor cells towards withanolides. Using IC 50 concentrations of eight different withanolides (withaferin A, withaferin A diacetate, 3-azerininylwithaferin A, withafastuosin D diacetate, 4-B-hydroxy-withanolide E, isowithanololide E, withafastuosin E, and withaperuvin) and 19 established anticancer drugs, we analyzed the cross-resistance profile of 60 tumor cell lines. The cell lines revealed cross-resistance between the eight withanolides. Consistent cross-resistance between withanolides and nitrosoureas (carmustin, lomustin, and semimustin) was also observed. Then, we performed transcriptomic microarray-based COMPARE and hierarchical cluster analyses of mRNA expression to identify mRNA expression profiles predicting sensitivity or resistance towards withanolides. Genes from diverse functional groups were significantly associated with response of tumor cells to withaferin A diacetate, e.g. genes functioning in DNA damage and repair, stress response, cell growth regulation, extracellular matrix components, cell adhesion and cell migration, constituents of the ribosome, cytoskeletal organization and regulation, signal transduction, transcription factors, and others.
References
[1]
Koehn, F.E.; Carter, G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 2005, 4, 206–220, doi:10.1038/nrd1657.
[2]
Efferth, T.; Li, P.; Kaina, B. From traditional Chinese medicine to rational cancer therapy. Trends Mol. Med. 2007, 13, 353–361, doi:10.1016/j.molmed.2007.07.001.
[3]
Schmidt, B.M.; Ribnicky, D.M.; Lipsky, P.E.; Raskin, I. Revisiting the ancient concept of botanical therapeutics. Nat. Chem. Biol. 2007, 3, 360–366, doi:10.1038/nchembio0707-360.
[4]
Efferth, T.; Kahl, S.; Paulus, K.; Adams, M.; Rauh, R.; Boechzelt, H.; Hao, X.; Kaina, B.; Bauer, R. Phytochemistry and pharmacogenomics of natural products derived from traditional Chinese medicine and Chinese Materia Medica with activity against tumour cells. Mol. Cancer Therap. 2008, 7, 152–161, doi:10.1158/1535-7163.MCT-07-0073.
[5]
Li, J.W.H.; Vederas, J.C. Drug discovery and natural products: End of an era or an endless frontier? Science 2009, 325, 161–165.
[6]
Mahringer, A.; Karamustafa, S.; Klotz, D.; Kahl, S.; Konkimalla, V.B.; Wang, Y.F.; Wang, J.S.; Liu, H.Y.; Boechzelt, H.; Hao, X.J.; Bauer, R.; Fricker, G.; Efferth, T. Inhibition of P-glycoprotein at the blood brain barrier by phytochemicals derived from traditional Chinese medicine. Cancer Genomics Proteomics 2010, 7, 191–205.
[7]
Efferth, T. Personalized cancer medicine: From molecular diagnostics to targeted therapy with natural products. Planta Med. 2010, 76, 1–12.
[8]
Efferth, T.; Koch, E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr. Drug Targ. 2011, 12, 122–132, doi:10.2174/138945011793591626.
[9]
Konkimalla, V.B.; Efferth, T. Molecular mechanisms and interactions responsible for radio- and chemoresistance of tumors and their modulation by natural products from Ayurveda. In Herbal Medicine. A Cancer Chemopreventive and Therapeutic Perspective; Arora, R., Ed.; Jaypee Brothers Medical Publishers Pvt. Ltd.: New Delhi, India; St. Louis, MI, USA, 2010; pp. 513–530.
[10]
Mishra, L.C.; Singh, B.B.; Dagenais, S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): A review. Altern. Med. Rev. 2000, 5, 334–336.
[11]
Modak, M.; Dixit, P.; Londhe, J.; Ghaskadbi, S.; Paul, A.; Devasagayam, T. Indian herbs and herbal drugs used for the treatment of diabetes. J. Clin. Biochem. Nutr. 2007, 40, 163–173, doi:10.3164/jcbn.40.163.
[12]
Lu, L.; Liu, Y.; Zhu, W.; Shi, J.; Liu, Y.; Ling, W.; Kosten, T.R. Traditional medicine in the treatment of drug addiction. Am. J. Drug Alcohol. Abuse 2009, 35, 1–11, doi:10.1080/00952990802455469.
[13]
Maurya, R. Chemistry and pharmacology of Withania coagulans: An Ayurvedic remedy. J. Pharm. Pharmacol. 2010, 62, 153–160, doi:10.1211/jpp.62.02.0001.
[14]
Ven Murthy, M.R.; Ranjekar, P.K.; Ramassamy, C.; Deshpande, M. Scientific basis for the use of Indian ayurvedic medicinal plants in the treatment of neurodegenerative disorders: Ashwagandha. Cent. Nerv. Syst. Agents Med. Chem. 2010, 10, 238–236.
[15]
Mirjalili, M.H.; Moyano, E.; Bonfill, M.; Cusido, R.M.; Palazón, J. Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules 2009, 14, 2373–2393, doi:10.3390/molecules14072373.
[16]
Rastogi, R.P.; Mehrotra, B.N. Compendium of Indian Medicinal Plants; Central Drug Research Institute: New Delhi, India; St. Louis, MI, USA, 1998.
[17]
Davis, L.; Kuttan, G. Effect of Withania somnifera on 20-methylcholanthrene induced fibrosarcoma. J. Exp. Clin. Cancer Res. 2000, 19, 165–167.
[18]
Davis, L.; Kuttan, G. Effect of Withania somnifera on DMBA induced carcinogenesis. J. Ethnopharmacol. 2001, 75, 165–168, doi:10.1016/S0378-8741(00)00404-9.
[19]
Prakash, J.; Gupta, S.K.; Kochupillai, V.; Singh, N.; Gupta, Y.K.; Joshi, S. Chemopreventive activity of Withania somnifera in experimentally induced fibrosarcoma tumours in Swiss albino mice. Phytother. Res. 2001, 15, 240–244, doi:10.1002/ptr.779.
[20]
Muralikrishnan, G.; Dinda, A.K.; Shakeel, F. Immunomodulatory effects of Withania somnifera on azoxymethane induced experimental colon cancer in mice. Immunol. Invest. 2010, 39, 688–698, doi:10.3109/08820139.2010.487083.
[21]
Sharada, A.C.; Solomon, F.E.; Devi, P.U.; Udupa, N.; Srinivasan, K.K. Antitumor and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma in vivo. Acta Oncol. 1996, 35, 95–100, doi:10.3109/02841869609098486.
[22]
Srinivasan, S.; Ranga, R.S.; Burikhanov, R.; Han, S.S.; Chendil, D. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res. 2007, 67, 246–243.
[23]
Stan, S.D.; Zeng, Y.; Singh, S.V. Ayurvedic medicine constituent withaferin a causes G2 and M phase cell cycle arrest in human breast cancer cells. Nutr. Cancer. , 60, 51–60.
[24]
Malik, F.; Kumar, A.; Bhushan, S.; Mondhe, D.M.; Pal, H.C.; Sharma, R.; Khajuria, A.; Singh, S.; Singh, G.; Saxena, A.K.; Suri, K.A.; Qazi, G.N.; Singh, J. Immune modulation and apoptosis induction: Two sides of antitumoural activity of a standardised herbal formulation of Withania somnifera. Eur. J. Cancer. 2009, 45, 1494–1509.
[25]
Yu, Y.; Hamza, A.; Zhang, T.; Gu, M.; Zou, P.; Newman, B.; Li, Y.; Gunatilaka, A.A.; Zhan, C.G.; Sun, D. Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem. Pharmacol. 2010, 79, 542–551, doi:10.1016/j.bcp.2009.09.017.
[26]
Hahm, E.R.; Lee, J.; Huang, Y.; Singh, S.V. Withaferin a suppresses estrogen receptor-α expression in human breast cancer cells. Mol. Carcinog. 2011, 50, 614–624, doi:10.1002/mc.20760.
[27]
Devi, P.U.; Akagi, K.; Ostapenko, V.; Tanaka, Y.; Sugahara, T. Withaferin A: A new radiosensitizer from the Indian medicinal plant Withania somnifera. Int. J. Radiat. Biol. 1996, 69, 193–197, doi:10.1080/095530096146020.
[28]
Stan, S.D.; Hahm, E.R.; Warin, R.; Singh, S.V. Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res. , 68, 7661–7669.
[29]
Mandal, C.; Dutta, A.; Mallick, A.; Chandra, S.; Misra, L.; Sangwan, R.S.; Mandal, C. Withaferin A induces apoptosis by activating p38 mitogen-activated protein kinase signaling cascade in leukemic cells of lymphoid and myeloid origin through mitochondrial death cascade. Apoptosis 2008, 13, 1450–1464, doi:10.1007/s10495-008-0271-0.
[30]
Choi, M.J.; Park, E.J.; Min, K.J.; Park, J.W.; Kwon, T.K. Endoplasmic reticulum stress mediates withaferin A-induced apoptosis in human renal carcinoma cells. Toxicol. In Vitro 2011, 25, 692–698, doi:10.1016/j.tiv.2011.01.010.
[31]
Mohan, R.; Hammers, H.J.; Bargagna-Mohan, P.; Zhan, X.H.; Herbstritt, C.J.; Ruiz, A.; Zhang, L.; Hanson, A.D.; Conner, B.P.; Rougas, J.; Pribluda, V.S. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis. 2004, 7, 115–122, doi:10.1007/s10456-004-1026-3.
[32]
Mathur, R.; Gupta, S.K.; Singh, N.; Mathur, S.; Kochupillai, V.; Velpandian, T. Evaluation of the effect of Withania somnifera root extracts on cell cycle and angiogenesis. J. Ethnopharmacol. 2006, 105, 336–341, doi:10.1016/j.jep.2005.11.020.
[33]
Choudhary, M.I.; Hussain, S.; Yousuf, S.; Dar, A.; Mudassar, A.-R. Chlorinated and diepoxy withanolides from Withania somnifera and their cytotoxic effects against human lung cancer cell line. Phytochemistry 2010, 71, 2205–2209.
[34]
Mondal, S.; Mandal, C.; Sangwan, R.; Chandra, S.; Mandal, C. Withanolide D induces apoptosis in leukemia by targeting the activation of neutral sphingomyelinase-ceramide cascade mediated by synergistic activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase. Mol. Cancer. 2010, 9, 239.
[35]
Abdeljebbar, L.H.; Benjouad, A.; Morjani, H.; Merghoub, N.; El Haddar, S.; Humam, M.; Christen, P.; Hostettmann, K.; Bekkouche, K.; Amzazi, S. Antiproliferative effects of withanolides from Withania adpressa. Therapie 2009, 64, 121–127.
[36]
Xu, Y.M.; Marron, M.T.; Seddon, E.; McLaughlin, S.P.; Ray, D.T.; Whitesell, L.; Gunatilaka, A.A. 2,3-Dihydrowithaferin A-3beta-O-sulfate, a new potential prodrug of withaferin A from aeroponically grown Withania somnifera. Bioorg. Med. Chem. 2009, 17, 2210–2214.
Subbaraju, G.V.; Vanisree, M.; Rao, C.V.; Sivaramakrishna, C.; Sridhar, P.; Jayaprakasam, B.; Nair, M.G. Ashwagandhanolide, a bioactive dimeric thiowithanolide isolated from the roots of Withania somnifera. J. Nat. Prod. 2006, 69, 1790–1792, doi:10.1021/np060147p.
[39]
Mathur, S.; Kaur, P.; Sharma, M.; Katyal, A.; Singh, B.; Tiwari, M.; Chandra, R. The treatment of skin carcinoma, induced by UV B radiation, using 1-oxo-5beta, 6beta-epoxy-witha-2-enolide, isolated from the roots of Withania somnifera, in a rat model. Phytomedicine 2004, 11, 452–460, doi:10.1016/j.phymed.2003.05.004.
[40]
Developmental Therapeutics Program NCI/NIH Hompage. Available online: http://dtp.nci.nih.gov (accessed on 21 May 2012).
[41]
Alley, M.C.; Scudiero, D.A.; Monks, A.; Hursey, M.L.; Czerwinski, M.J.; Fine, D.L.; Abbott, B.J.; Mayo, J.G.; Shoemaker, R.H.; Boyd, M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988, 48, 589–601.
[42]
Monk, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 1991, 83, 757–756, doi:10.1093/jnci/83.11.757.
[43]
Staunton, J.E.; Slonim, D.K.; Coller, H.A.; Tamayo, P.; Angelo, M.J.; Park, J.; Scherf, U.; Lee, J.K.; Reinhold, W.O.; Weinstein, J.N.; Mesirov, J.P.; Lander, E.S.; Golub, T.R. Chemosensitivity prediction by transcriptional profiling. Proc. Natl. Acad. Sci. USA 2001, 98, 10787–10792.
[44]
OMIM？—nline Mendelian Inheritance in Man？ Hompage. Available online: http://www.ncbi.nlm.nih.gov/Omim (accessed on 21 May 2012).
[45]
GeneCard database. Weizman Institute of Science: Rehovot, Israel. 2012. Available online: http://bioinfo.weizmann.ac.il/cards/index.html (accessed on 21 May 2012).
[46]
Efferth, T.; Dunstan, H.; Sauerbrey, A.; Miyachi, H.; Chitambar, C.R. The antimalarial artesunate is also a potent anticancer drug. Int. J. Oncol. 2001, 18, 767–773.
[47]
Efferth, T.; Kahl, S.; Paulus, K.; Adams, M.; Rauh, R.; Boechzelt, H.; Hao, X.; Kaina, B.; Bauer, R. Phytochemistry and pharmacogenomics of natural products derived from traditional Chinese medicine and chinese materia medica with activity against tumor cells. Mol. Cancer Ther. 2008, 7, 152–161.
[48]
Sertel, S.; Eichhorn, T.; Bauer, J.; Hock, K.; Plinkert, P.K.; Efferth, T. Pharmacogenomic determination of genes associated with sensitivity or resistance of tumor cells to curcumin and curcumin derivatives. J. Nutr. Biochem. 2011. in press.
[49]
Koduru, S.; Kumar, R.; Srinivasan, S.; Evers, M.B.; Damodaran, C. Notch-1 inhibition by Withaferin-A: A therapeutic target against colon carcinogenesis. Mol. Cancer Ther. 2010, 9, 202–210.
[50]
Senthilnathan, P.; Padmavathi, R.; Magesh, V.; Sakthisekaran, D. Chemotherapeutic efficacy of paclitaxel in combination with Withania somnifera on benzo(a)pyrene-induced experimental lung cancer. Cancer Sci. 2006, 97, 658–664, doi:10.1111/j.1349-7006.2006.00224.x.
[51]
Kalthur, G.; Pathirissery, U.D. Enhancement of the response of B16F1 melanoma to fractionated radiotherapy and prolongation of survival by withaferin A and/or hyperthermia. Integr. Cancer Ther. 2010, 9, 370–377, doi:10.1177/1534735410378664.
[52]
Yang, E.S.; Choi, M.J.; Kim, J.H.; Choi, K.S.; Kwon, T.K. Withaferin A enhances radiation-induced apoptosis in Caki cells through induction of reactive oxygen species, Bcl-2 downregulation and Akt inhibition. Chem. Biol. Interact. 2011, 190, 9–15, doi:10.1016/j.cbi.2011.01.015.
[53]
Leteurtre, F.; Kohlhagen, G.; Paull, K.D.; Pommier, Y. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen. J. Natl. Cancer Inst. 1994, 86, 1239–1244, doi:10.1093/jnci/86.16.1239.
[54]
Efferth, T.; Gebhart, E.; Ross, D.D.; Sauerbrey, A. Identification of gene expression profiles predicting tumor cell response to l-alanosine. Biochem. Pharmacol. 2003, 66, 613–621, doi:10.1016/S0006-2952(03)00341-1.
[55]
Efferth, T.; Olbrich, A.; Bauer, R. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem. Pharmacol. 2002, 64, 617–623, doi:10.1016/S0006-2952(02)01221-2.
[56]
Thaiparambil, J.T.; Bender, L.; Ganesh, T.; Kline, E.; Patel, P.; Liu, Y.; Tighiouart, M.; Vertino, P.M.; Harvey, R.D.; Garcia, A.; Marcus, A.I. Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. Int. J. Cancer. 2011, 129, 2744–2755.
[57]
Conner, B.P.; Rougas, J.; Pribluda, V.S. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 2004, 7, 115–122, doi:10.1007/s10456-004-1026-3.
[58]
Grover, A.; Shandilya, A.; Punetha, A.; Bisaria, V.S.; Sundar, D. Inhibition of the NEMO/IKKβ association complex formation, a novel mechanism associated with the NF-κB activation suppression by Withania somnifera’s key metabolite withaferin A. BMC Genomics. 2010, 11, 25.
[59]
Grover, A.; Shandilya, A.; Agrawal, V.; Pratik, P.; Bhasme, D.; Bisaria, V.S.; Sundar, D. Hsp90/Cdc37 chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A. BMC Bioinformatics 2011, 12, 30.
[60]
Swagemakers, S.M.; Essers, J.; de Wit, J.; Hoeijmakers, J.H.; Kanaar, R. The human RAD54 recombinational DNA repair protein is a double-stranded DNA-dependent ATPase. J. Biol. Chem. 1998, 273, 28292–28297.
[61]
Fuqua, S.A.; Oesterreich, S.; Hilsenbeck, S.G.; Von Hoff, D.D.; Eckardt, J.; Osborne, C.K. Heat shock proteins and drug resistance. Breast Cancer Res. Treat. 1994, 32, 67–71, doi:10.1007/BF00666207.
[62]
Zhang, F.; Zhang, L.; Zhang, B.; Wei, X.; Yang, Y.; Qi, R.Z.; Ying, G.; Zhang, N.; Niu, R. Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells. J. Proteome Res. 2009, 8, 5041–5047, doi:10.1021/pr900461c.
[63]
Gong, X.G.; Lv, Y.F.; Li, X. Q.; Xu, F.G.; Ma, Q.Y. Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells. Biol. Pharm. Bull. 2010, 33, 1261–1267, doi:10.1248/bpb.33.1261.
[64]
Chen, H.; Xie, Z.X.; Jiang, H.; Zhang, Z.W.; Wang, G.P. Effect of ribosomal protein L6 on drug resistance and apoptosis in K562/A02 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007, 15, 292–295.
[65]
Harris, E.H.; Burkhart, B.D.; Gillham, N.W.; Boynton, J.E. Antibiotic resistance mutations in the chloroplast 16S and 23S rRNA genes of Chlamydomonas reinhardtii: Correlation of genetic and physical maps of the chloroplast genome. Genetics. 1989, 123, 281–292.
[66]
Stolovich, M.; Tang, H.; Hornstein, E.; Levy, G.; Cohen, R.; Bae, S.S.; Birnbaum, M.J.; Meyuhas, O. Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinasemediated pathway but requires neither S6K1 nor rpS6 phosphorylation. Mol. Cell Biol. 2002, 22, 8101–8113.
[67]
Du, J.; Shi, Y.; Pan, Y.; Jin, X.; Liu, C.; Liu, N.; Han, Q.; Lu, Y.; Qiao, T.; Fan, D. Regulation of multidrug resistance by ribosomal protein l6 in gastric cancer cells. Cancer Biol. Ther. 2005, 4, 242–247, doi:10.4161/cbt.4.2.1477.
[68]
Efferth, T.; Miyachi, H.; Bartsch, H. Pharmacogenomics of a traditional Japanese herbal medicine (Kampo) for cancer therapy. Cancer Genomics Proteomics 2007, 4, 81–92.
[69]
Sertel, S.; Eichhorn, T.; Sieber, S.; Sauer, A.; Weiss, J.; Plinkert, P.K.; Efferth, T. Efferth, T. Factors determining sensitivity or resistance of tumor cell lines towards artesunate. Chem-Biol. Interact. 2010, 185, 42–52, doi:10.1016/j.cbi.2010.02.002.
[70]
Scherf, U.; Ross, D.T.; Waltham, M.; Smith, L.H.; Lee, J.K.; Tanabe, L.; Kohn, K.W.; Reinhold, W.C.; Myers, T.G.; Andrews, D.T.; et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 2000, 24, 236–244, doi:10.1038/73439.
[71]
Amundson, S.A.; Do, K.T.; Vinikoor, L.C.; Lee, R.A.; Koch-Paiz, C.A.; Ahn, J.; Reimers, M.; Chen, Y.; Scudiero, D.A.; Weinstein, J.N.; et al. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res. 2008, 68, 415–424.
[72]
Efferth, T.; Fabry, U.; Osieka, R. Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia 1997, 11, 1180–1186.
[73]
Wosikowski, K.; Schuurhuis, D.; Johnso, K.; Paull, K.D.; Myers, T.G.; Weinstein, J.N.; Bates, S.E. Identification of epidermal growth factor receptor and erbB2 pathway inhibitors by correlation with gene expression patterns. J. Natl. Cancer Inst. 1997, 89, 1505–1515, doi:10.1093/jnci/89.20.1505.
